HALEON US HOLDINGS
SpecialtyHALEON US HOLDINGS is a specialty pharmaceutical company focused on Gastroenterology. Key products include ADVIL ALLERGY AND CONGESTION RELIEF.
HALEON US HOLDINGS at a Glance
- Strong track record with 85% execution quality across 17 trials
- Fast trial execution (2 months median completion)
HALEON US HOLDINGS's Key Drugs
HALEON US HOLDINGS's core commercial portfolio centers on ADVIL DUAL ACTION WITH ACETAMINOPHEN, FLONASE ALLERGY RELIEF, ADVIL ALLERGY AND CONGESTION RELIEF, spanning Gastroenterology — its most strategically important drugs approved in the last 15 years.
HALEON US HOLDINGS's Recent FDA Approvals
New NDA/BLA approvals for HALEON US HOLDINGS over the last two years — novel drugs only, excluding generics and label supplements.
HALEON US HOLDINGS's Therapeutic Areas
HALEON US HOLDINGS's approved drugs and pipeline span 1 therapeutic area, led by Gastroenterology, across 0 biologic and 24 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HALEON US HOLDINGS's Top Competitors
HALEON US HOLDINGS's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HALEON US HOLDINGS Pipeline Snapshot
HALEON US HOLDINGS has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ADVIL DUAL ACTION WITH ACETAMINOPHEN leads revenue
- • 4 key drugs tracked
Trial Catalysts
- • Gastroenterology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/3 completed
- • Speed: 2 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (4)
Discontinued (0)
Company Info
- First Approval
- 1984-01-13
- Latest
- 2026-05-01
- Applications
- 31
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges